Treatment of refractory myositis. A randomized crossover study of two new cytotoxic regimens

Arthritis and Rheumatism

Volumn 41, Issue 3, 1998, Pages 392-399

  Villalba, Lourdes ^a   Hicks, Jeanne E ^b   Adams, Elizabeth M ^a   Sherman, Jeffrey B ^a   Gourley, Mark F ^a   Leff, Richard L ^a   Thornton, Bonnie C ^b   Burgess, Suzanne H ^b   Plotz, Paul H ^a   Miller, Frederick W ^c  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; FOLINIC ACID; METHOTREXATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOTOXICITY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUSCLE FUNCTION; MUSCLE STRENGTH; MYOSITIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTIRHEUMATIC AGENTS; AZATHIOPRINE; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MALE; METHOTREXATE; MIDDLE AGED; MYOSITIS; SALVAGE THERAPY;

EID: 0031931357     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X     Document Type: Article

References (29)

1. Adams EM, Plotz PH. The treatment of myositis: how to approach resistant disease. Rheum Dis Clin North Am 1995;21:179-202.
2. Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 1981;24:45-8.
3. Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med 1980;92:365-9.
4. Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992;326: 1380-4.
5. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
6. Willkens RF, Urowitz MB, Stablein DM, McKendry RJR Jr, Berger RG, Box JH, et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992;35: 849-56.
7. McKendry RJ. Azathioprine and methotrexate as combination chemotherapy in rheumatoid arthritis. J Rheumatol Suppl 1990; 25:28-33.
8. Shiroky JB, Neville C, Skelton JD. High dose intravenous methotrexate for refractory rheumatoid arthritis. J Rheumatol 1992;19: 247-51.
9. Shiroky J, Allegra C, Inghirami G, Chabner B, Yarboro C, Klippel JH. High dose intravenous methotrexate with leucovorin rescue in rheumatoid arthritis. J Rheumatol 1988;15:251-5.
10. Cronin ME, Miller FW, Hicks JE, Dalakas M, Plotz PH. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989;16:1225-8.
11. Leff RL, Miller FW, Hicks J, Fraser DD, Plotz PH. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine (Baltimore) 1993;72:225-35.
12. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
13. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
14. Fraser DD, Frank JA, Dalakas M, Miller FW, Hicks JE, Plotz P. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 1991;18:1693-700.
15. Adams EM, Chow CK, Premkumar A, Plotz PH. The idiopathic inflammatory myopathies: spectrum of MR imaging findings. Radiographies 1995;15:563-74.
16. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993;94: 379-87.
17. Watkins MP, Harris BA. Evaluation of skeletal muscle performance. In: Harms-Ringdahl K, editor. Muscle strength. London: Churchill Livingstone; 1993. p. 19.
18. Hicks JE. Rehabilitation of patients with myositis. In: Klippel JH, Dieppe PA, editors. Rheumatology. Boston: Mosby; 1994. p. 15.4.
19. Daniels L, Worthingham C. Muscle testing. 3rd ed. Philadelphia: WB Saunders; 1972.
20. Convery MR, Minteer MA, Amiel D, Connett KL. Polyarticular disability: a functional assessment. Arch Phys Med Rehabil 1977; 58:494-9.
21. Jones B, Kenward M. Design and analysis of crossover designs. New York: Chapman Hall; 1989. p. 92-100.
22. Blanco R, Martlnez-Taboada VM, González-Gay MA, Armona J, Fernández-Sueiro JL, Gonzalez-Vela MC, et al. Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Arthritis Rheum 1996;39:1016-20.
23. Louis T, Lavori P, Bailar J, Polanski M. Crossover and self-controlled designs in clinical research. In: Bailar JCI, Mosteller F, editors. Medical uses of statistics. Waltham, MA: NEJM Books; 1992. p. 83.
24. Shiroky JB, Neville C, Esdaile JM, Choquette D, Zummer M, Hazeltine M, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1993;36:795-803.
25. Weinblatt ME, Maier AL, Coblyn JS. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. J Rheumatol 1993;20:950-2.
26. Avina-Zubieta JA, Enkerlin HL, Galindo-Rodriguez G. Rheumatic manifestations of malignancy. Curr Opin Rheumatol 1996; 8:47-51.
27. Krishnan K, Adams P, Silveira S, Sheldon S, Dabich L. Therapy-related acute myeloid leukaemia following immunosuppression with azathioprine for polymyositis. Clin Lab Haematol 1994;16: 285-9.
28. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74.
29. Miller FW. Myositis-specific autoantibodies: touchstones for understanding the inflammatory myopathies. JAMA 1993;270:1846-9.